To that end, we examined the effectiveness of using modified MSCs for the systemic delivery of an oncolytic adenovirus expressing small hairpin RNAs (shRNAs) targeting both HSP27 and TGF-β1 to determine whether this approach could improve the tumor bioavailability of systemically administered oncolytic adenovirus. This evidence concerns the gene TGFB1 and neoplasm.